Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer’s disease models
Anusha R. Pallapati, et al.
Anusha R. Pallapati, et al.
View: Text | PDF
Research Article Endocrinology

Efficacy and safety of a therapeutic humanized FSH-blocking antibody in obesity and Alzheimer’s disease models

  • Text
  • PDF
Abstract

There is growing evidence for direct actions of follicle-stimulating hormone (FSH) on tissues other than the ovaries and testes. Blocking FSH action, either genetically or pharmacologically, protects against bone loss, fat gain, and memory loss in mice. We thus developed a humanized FSH-blocking antibody, MS-Hu6, as a lead therapeutic for 3 diseases of public health magnitude — osteoporosis, obesity, and Alzheimer’s disease (AD) — that track together in postmenopausal women. Here, we report the crystal structure of MS-Hu6 and its interaction with FSH in atomistic detail. Using our Good Laboratory Practice platform (21 CFR 58), we formulated MS-Hu6 and the murine equivalent, Hf2, at an ultra-high concentration; both formulated antibodies displayed enhanced thermal and colloidal stability. A single injection of 89Zr-labeled MS-Hu6 revealed a β phase t½ of 79 and 132 hours for female and male mice, respectively, with retention in regions of interest. Female mice injected subcutaneously with Hf2 displayed a dose-dependent reduction in body weight and body fat, in the face of reduced free (bioavailable) FSH and unperturbed estrogen levels. Hf2 also rescued recognition memory and spatial learning loss in a context- and time-dependent manner in AD-prone 3xTg and APP/PS1 mice. MS-Hu6 injected into African green monkeys (8 mg/kg) intravenously, and then subcutaneously at monthly intervals, was safe, and without effects on vital signs, blood chemistries, or blood counts. There was a notable approximately 4% weight loss in all 4 monkeys after the first injection, which continued in 2 of the monkeys. We thus provide Investigational New Drug–enabling data for a planned first-in-human study.

Authors

Anusha R. Pallapati, Funda Korkmaz, Satish Rojekar, Steven Sims, Anurag Misra, Judit Gimenez-Roig, Aishwarya Gangadhar, Victoria Laurencin, Anisa Gumerova, Uliana Cheliadinova, Farhath Sultana, Darya Vasilyeva, Liam Cullen, Jonathan Schuermann, Jazz Munitz, Hasni Kannangara, Surabhi Parte, Georgii Pevnev, Guzel Burganova, Zehra Tumoglu, Ronit Witztum, Soleil Wizman, Natan Kramskiy, Liah Igel, Fazilet Sen, Anna Ranzenigo, Anne Macdonald, Susan Hutchison, Abraham J.P. Teunissen, Heather Burkart, Mansi Saxena, Yelena Ginsburg, Ki Goosens, Weibin Zhou, Vitaly Ryu, Ofer Moldavski, Orly Barak, Michael Pazianas, John Caminis, Shalender Bhasin, Richard Fitzgerald, Se-Min Kim, Matthew Quinn, Shozeb Haider, Susan Appt, Tal Frolinger, Clifford J. Rosen, Daria Lizneva, Yogesh K. Gupta, Tony Yuen, Mone Zaidi

×

Figure 3

Hf2 protects against domain-specific and time-dependent memory loss in AD-prone mice.

Options: View larger image (or click on image) Download as PowerPoint
Hf2 protects against domain-specific and time-dependent memory loss in A...
(A) Groups of ovariectomized or aged AD-prone mice were injected with Hf2 and subjected to the novel object recognition (NOR) test for recognition memory and the Morris water maze (MWM) test for learning and spatial memory acquisition (training phase), and retrieval of consolidated spatial memory (probe trial). (B) A prevention protocol involved injection of Hf2 into ovariectomized 3xTg mice, initially for 8 weeks, and then for a further 12 weeks for a total of 20 weeks. (C–E) With Hf2, there was a significant (P = 0.048) increase in novel object interactions at 8 weeks, but not at 20 weeks (C), a significant (P = 0.002) reduction in latency to platform at 20 weeks, but not at 8 weeks (D), and no difference in spatial memory retrieval (time in the 40 cm platform zone) (probe trial) at either time point (E) (n = 7 mice per group). (F–I) In a treatment protocol, Hf2 was injected into 15-month-old 3xTg mice for 12 weeks (F); this revealed no effect on object interactions in the NOR test (G), a marked (P = 0.06) reduction in latency to platform (H), and no effect on the probe trial in the MWM test (I) (n = 6–7 mice per group). (J–L) A complementary treatment protocol in which Hf2 was injected into 18- to 22-month-old APP/PS1 mice for 12 weeks (J) revealed a significant (P = 0.03) increase in novel object interaction (K), but no difference in latency to platform (L) (n = 10–12 mice per group). Statistics: Two-tailed Student’s t test; mean ± SEM. AUC, area under the curve.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts